Skip to main content

Table 6 MTHFR (C677T and A1298C) gene polymorphisms with its relative frequencies in poor seizures controlled and seizure controlled patients at 6th month of carbamazepine therapy

From: Epilepsy control with carbamazepine monotherapy from a genetic perspective

N = 62 Carbamazepine resistant patients (n = 34) Carbamazepine responsive patients (n = 28)
Variables Total Total
Number (%) 34 (55) 28 (45)
Genotypes
 677CC 9 20
 677CT 15 5
 677TT 10 3
 1298AA 11 21
 1298 AC 14 4
 1298CC 9 3
  1. MTHFR (C677T) Gene
  2. Heterozygous (677CT) genotypes were more likely frequent in carbamazepine resistant patients compared to carbamazepine responsive patients (χ2 = 7.5, P = 0.002**) comparing total patients of carbamazepine resistant VS total patients who are responsive to carbamazepine therapy. Similarly, Homozygous(677TT) genotypes were more likely frequent in carbamazepine therapy resistant patients as compared to carbamazepine responsive patients (χ2 = 5.9, P = 0.01*).
  3. MTHFR (A1298C) Gene
  4. Heterozygous (1298 AC) genotypes were more likely frequent in carbamazepine resistant patients compared to carbamazepine responsive patients (χ2 = 7.03, P = 0.008**) comparing total patients of carbamazepine resistant VS total patients who are responsive to carbamazepine therapy.
  5. Similarly, homozygous (1298CC)genotypes were more likely frequent in carbamazepine therapy resistant patients as compared to carbamazepine responsive patients (χ2 = 4.3, P = 0.03*).